Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 06 - 29 tags : Phase 2 save search
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
HZNP | $116.3 0.03% 29M
|
Health Technology
|
| O: -0.08%
H: 0.66%
C: -0.95%
treatment phase 2 trial lupus enroll
Harmony Biosciences Initiates A Phase 2 Clinical Trial In Myotonic Dystrophy
Published: 2021-06-29 (Crawled : 14:00) - biospace.com/
HRMY | $29.165 0.47% 79K
|
Health Technology
|
| O: 0.24%
H: 1.81%
C: -0.92%
phase 2 trial bioscience
VBI Vaccines Announces Initial Positive Phase 1 Data for its eVLP Vaccine Candidate Against COVID-19
Published: 2021-06-29 (Crawled : 12:00) - vbivaccines.com
VBIV | $0.639 1.48% 43K
|
Health Technology
|
| O: 2.59%
H: 4.76%
C: -9.58%
covid phase 1 positive vaccine phase 2 phase 3 covid-19
Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease
Published: 2021-06-29 (Crawled : 12:00) - prnewswire.com
PTN | $1.86 -1.59% 75K
|
Health Technology
|
| O: 7.22%
H: 15.17%
C: 15.17%
dry eye disease treatment fda phase 2 eye positive eye disease
Yamana Gold Provides Notice of Second Quarter 2021 Results and Notice Relating to Updates on Phase 2 Expansion at Jacobina and Construction of the Odyssey Project and Wasamac Project
Published: 2021-06-29 (Crawled : 12:00) - globenewswire.com
AUY | $5.85 -0.68% -0.51% 0
|
Non-Energy Minerals
|
| O: -1.65%
H: 1.43%
C: 0.24%
phase 2 expansion results
DiaMedica Therapeutics Announces Positive Interim Results from Phase 2 REDUX Study in CKD
Published: 2021-06-29 (Crawled : 12:00) - biospace.com/
DMAC | $2.49 1.5K
|
Health Technology
|
| O: -26.78%
H: 0.76%
C: -9.71%
phase 2 positive results
IONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical Trial
Published: 2021-06-29 (Crawled : 11:00) - biospace.com/
FSTX | $7.12 0.0% 0
|
Health Technology
|
| O: -0.78%
H: 4.26%
C: -1.68%
phase 1 collaboration trial phase 2 phase 3
Addex Therapeutics Initiates Pivotal Phase 2b/3 Study with Dipraglurant for Dyskinesia Associated with Parkinson’s Disease
Published: 2021-06-29 (Crawled : 06:00) - globenewswire.com
ADXN | News | $18.3 -12.69% 11K
|
Health Technology
|
| O: 1.4%
H: 2.07%
C: -0.56%
disease phase 2 parkinson phase 2b skin
Gainers vs Losers
| 76% | 24% |
Top 10 Gainers
AGBA | News | $1.22 205.0% 86M
|
Finance
EGOX | $0.054 50.0% 290M
|
CHRO | $1.66 35.51% 70K
|
n/a
INDO | $5.43 33.09% 10M
|
Energy Minerals
NVFY | $2.71 28.44% 31M
|
Consumer Durables
ZCMD | $1.86 28.28% 29M
|
Commercial Services
RWOD | $10.08 26.05% 5.6M
|
n/a
HUSA 4 | $2.07 23.95% 2.1M
|
Energy Minerals
TPET | $0.4001 22.02% 35M
|
n/a
SRFM 4 | $0.6 21.29% 850K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.